FR3104946B1 - Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis - Google Patents

Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis Download PDF

Info

Publication number
FR3104946B1
FR3104946B1 FR1915517A FR1915517A FR3104946B1 FR 3104946 B1 FR3104946 B1 FR 3104946B1 FR 1915517 A FR1915517 A FR 1915517A FR 1915517 A FR1915517 A FR 1915517A FR 3104946 B1 FR3104946 B1 FR 3104946B1
Authority
FR
France
Prior art keywords
psoriasis
inflammatory
treatment
dendrimer
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1915517A
Other languages
English (en)
Other versions
FR3104946A1 (fr
Inventor
Muriel Blanzat
Ranime Jebbawi
Rémy Poupot
Cédric-Olivier Turrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1915517A priority Critical patent/FR3104946B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU2020412366A priority patent/AU2020412366A1/en
Priority to EP20851221.0A priority patent/EP4081191A1/fr
Priority to CA3165406A priority patent/CA3165406A1/fr
Priority to IL294186A priority patent/IL294186A/en
Priority to PCT/FR2020/052608 priority patent/WO2021130453A1/fr
Priority to US17/787,787 priority patent/US20230085651A1/en
Publication of FR3104946A1 publication Critical patent/FR3104946A1/fr
Application granted granted Critical
Publication of FR3104946B1 publication Critical patent/FR3104946B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet des vésicules de tensioactifs catanioniques dérivés de sucre comprenant des dendrimères anti-inflammatoires et leur utilisation en tant que médicament, plus particulièrement dans le traitement du psoriasis.
FR1915517A 2019-12-23 2019-12-23 Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis Active FR3104946B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1915517A FR3104946B1 (fr) 2019-12-23 2019-12-23 Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis
EP20851221.0A EP4081191A1 (fr) 2019-12-23 2020-12-22 Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis
CA3165406A CA3165406A1 (fr) 2019-12-23 2020-12-22 Formulation d'un dendrimere anti-inflammatoire pour le traitement de psoriasis
IL294186A IL294186A (en) 2019-12-23 2020-12-22 Preparations containing dendrimers with anti-inflammatory activity for the treatment of psoriasis
AU2020412366A AU2020412366A1 (en) 2019-12-23 2020-12-22 Anti-inflammatory dendrimer formulation for the treatment of psoriasis
PCT/FR2020/052608 WO2021130453A1 (fr) 2019-12-23 2020-12-22 Formulation d'un dendrimère anti-inflammatoire pour le traitement de psoriasis
US17/787,787 US20230085651A1 (en) 2019-12-23 2020-12-22 Anti-inflammatory dendrimer formulation for the treatment of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1915517 2019-12-23
FR1915517A FR3104946B1 (fr) 2019-12-23 2019-12-23 Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis

Publications (2)

Publication Number Publication Date
FR3104946A1 FR3104946A1 (fr) 2021-06-25
FR3104946B1 true FR3104946B1 (fr) 2022-08-12

Family

ID=69903584

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1915517A Active FR3104946B1 (fr) 2019-12-23 2019-12-23 Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis

Country Status (7)

Country Link
US (1) US20230085651A1 (fr)
EP (1) EP4081191A1 (fr)
AU (1) AU2020412366A1 (fr)
CA (1) CA3165406A1 (fr)
FR (1) FR3104946B1 (fr)
IL (1) IL294186A (fr)
WO (1) WO2021130453A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862651B1 (fr) 2003-11-24 2006-03-31 Rhodia Cons Spec Ltd Nouveaux dendrimeres a terminaisons bisphosphoniques et derives, leur procede de preparation et leur utilisation
US20100173871A1 (en) * 2008-08-01 2010-07-08 Centre National De La Recherche Scientifique Phosphorylated dendrimers as antiinflammatory drugs

Also Published As

Publication number Publication date
EP4081191A1 (fr) 2022-11-02
US20230085651A1 (en) 2023-03-23
CA3165406A1 (fr) 2021-07-01
IL294186A (en) 2022-08-01
FR3104946A1 (fr) 2021-06-25
WO2021130453A1 (fr) 2021-07-01
AU2020412366A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
MA44674A (fr) Inhibiteurs de bromodomaine
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
EA202092086A1 (ru) Ингибиторы аргиназы
AR079479A1 (es) Composiciones oftalmicas no irritantes de povidona iodada
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA38556A1 (fr) Inhibiteurs de bace1
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA50406B1 (fr) Inhibiteurs pyrazole de magl
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA40875B1 (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
BR112022008365A2 (pt) Inibidores de cd73
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
EA201990560A1 (ru) Композиции, содержащие тритерпеноиды, и их применение для лечения оптической нейропатии
MA54663A1 (fr) Composition pharmaceutique aqueuse d'un anticorps anti-il17a et son utilisation
BR112022000855A2 (pt) Moduladores de nlrp3
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
FR3088542B1 (fr) Composition cicatrisante comprenant une eau électrolysée
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
MA20150235A1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210625

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5